Administration of Anti-EGFR Therapy: A Practical Review
Objectives
To highlight key issues in the administration of cancer therapies that target the EGFR.
Data Sources
Published clinical trials of anti-EGFR therapy, secondary literature on the administration of anticancer drugs, and illustrative case study reports.
Conclusion
Anti-EGFR agents represent a new class of therapy. It is important for nurses to acquire familiarity with the specific issues related to the administration of anti-EGFR agents. Preparedness and active patient monitoring can minimize the impact of toxicities (including interstitial lung disease, infusion reactions, and metabolic alterations) and help ensure the delivery of full treatment courses.
Implications for Nursing Practice
Nurses familiar with the administration issues and the severe adverse events associated with anti-EGFR therapy will be better equipped to manage them effectively.
To access this article, please choose from the options below
Supported in part by a grant from Bristol-Myers Squibb Company.
PII: S0749-2081(06)00035-0
doi:10.1016/j.soncn.2006.01.012
© 2006 Elsevier Inc. All rights reserved.
